We create the first agentic AI operating system to find the right treatment for every patient.

OWKIN is pioneering the first Biological Artificial Super Intelligence (BASI) to decode biology and develop tailored solutions for every patient. At the core of this innovation is OWKIN K, a next-generation agentic operating system that seamlessly connects multimodal patient data from top hospitals worldwide to AI agents that co-pilot tasks across biology, drug discovery, and diagnostics. Leveraging this ecosystem, OWKIN is launching new industry verticals led by AI agents, starting with Therakin (a next-gen ASI-driven pharma), OWKIN Dx (ASI-powered diagnostics), and BioOptimus (a foundation model for biology).

Owkin group has raised over $400 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

artificial intelligence, omics technology, oncology, drug discovery, medical research, biomedical images, real-world data, radiology, clinical data, federated learning, clinical tools, digital pathology, healthcare, diagnostic solutions, biomarkers, precision medicine, and data science